Tango Therapeutics, Inc. (TNGX) Tops Q3 EPS by 10c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.27), $0.10 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $11.61 million versus the consensus estimate of $8.07 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Freedom Broker Starts Unity Bancorp (UNTY) at Hold
• Crusoe in talks to raise $3B in funding - Bloomberg